FOXO3 programs tumor-associated DCs to become tolerogenic in human and murine prostate cancer. - Wikidata - awgldk - TriplyDB

FOXO3 programs tumor-associated DCs to become tolerogenic in human and murine prostate cancer.

FOXO3 programs tumor-associated DCs to become tolerogenic in human and murine prostate cancer.

http://www.wikidata.org/entity/Q34755205

about

MicroRNA-Regulated Proinflammatory Cytokines in Sarcopenia Dendritic Cells in Oncolytic Virus-Based Anti-Cancer Therapy Tumor-infiltrating dendritic cells in cancer pathogenesis Innate and adaptive immune cells in the tumor microenvironment The STING pathway and the T cell-inflamed tumor microenvironment Dendritic cell-based vaccination in cancer: therapeutic implications emerging from murine models User-friendly solutions for microarray quality control and pre-processing on ArrayAnalysis.org Regulatory dendritic cells: there is more than just immune activation Anti-tumor immunity: myeloid leukocytes control the immune landscape Pathological mobilization and activities of dendritic cells in tumor-bearing hosts: challenges and opportunities for immunotherapy of cancer Coordinated regulation of myeloid cells by tumours The dark side of dendritic cells: development and exploitation of tolerogenic activity that favor tumor outgrowth and immune escape.Cluster of differentiation 45 activation is crucial in interleukin-10-dependent tumor-associated dendritic cell differentiation.CD8+ T-cell responses rapidly select for antigen-negative tumor cells in the prostate.Whole-body irradiation increases the magnitude and persistence of adoptively transferred T cells associated with tumor regression in a mouse model of prostate cancer Transforming growth factor β-mediated suppression of antitumor T cells requires FoxP1 transcription factor expression Indoleamine 2,3 dioxygenase and metabolic control of immune responses.The immunosuppressive tumour network: myeloid-derived suppressor cells, regulatory T cells and natural killer T cells.High-avidity T cells are preferentially tolerized in the tumor microenvironment Dendritic cell-based vaccines: barriers and opportunities Stromal-dependent tumor promotion by MIF family members.Dendritic cell-specific delivery of Flt3L by coronavirus vectors secures induction of therapeutic antitumor immunity FoxO3 is a negative regulator of primary CD8+ T-cell expansion but not of memory formation Balancing the innate immune system in tumor development.Gene therapy for cancer: present status and future perspective Summary of the 2014 Alcohol and Immunology Research Interest Group (AIRIG) meeting Challenges and future perspectives of T cell immunotherapy in cancer Small RNA and its application in andrology and urology Tolerogenic dendritic cells and their applications in transplantation Cell-intrinsic abrogation of TGF-β signaling delays but does not prevent dysfunction of self/tumor-specific CD8 T cells in a murine model of autochthonous prostate cancer Isolation of immune cells from primary tumors.Didymin reverses phthalate ester-associated breast cancer aggravation in the breast cancer tumor microenvironment Measles virus nucleocapsid protein, a key contributor to Paget's disease, increases IL-6 expression via down-regulation of FoxO3/Sirt1 signaling.Immune Regulation by Self-Recognition: Novel Possibilities for Anticancer Immunotherapy.Murine dendritic cell rapamycin-resistant and rictor-independent mTOR controls IL-10, B7-H1, and regulatory T-cell induction Indoleamine 2,3-dioxygenase and dendritic cell tolerogenicity.Immunotherapy: shifting the balance of cell-mediated immunity and suppression in human prostate cancer.Highlights on FOXO3 and tumor-associated dendritic cells in prostate cancer.Human SNP links differential outcomes in inflammatory and infectious disease to a FOXO3-regulated pathway.Stressful presentations: mild cold stress in laboratory mice influences phenotype of dendritic cells in naïve and tumor-bearing mice.

P2860

Q26744385-282E2D70-CB09-42FC-B436-7509CE58B55F Q26774345-88BD2F6A-BDFC-43BC-959E-13E55745641B Q26861633-9478E29E-AA43-4150-BC6A-B3C2A6FD8C6D Q27008342-A8801F15-0809-4C60-A296-05E9E4658109 Q27008371-C453025D-F79E-4F52-AC2E-C770E931D1FF Q27012618-3A32CB12-7D21-4FA0-AD18-39F9A5E11F3C Q27990280-A7B92D50-EE7D-4CF9-8106-A0D19633D4BC Q28388235-828CB30D-3E9C-4D3B-9866-07D3E155CA8E Q28390573-EB55C8F0-AB38-44D0-B0B3-B80411A2577E Q28392626-A2CE29EA-6787-417A-A5D8-CBF866A357E0 Q28395157-1702AE6A-0BF8-483A-9274-BED385A55AA0 Q30317628-022C22B4-FC83-43DF-ADCA-0EE1E0D3B36C Q33844094-6ADC9AE2-4461-4B10-9B1A-DC56CDA4500C Q33931006-9F9B5728-EFE4-473E-A0AF-C43A696F26CE Q34016750-1B53074F-023E-44C2-8069-BABA41244DA3 Q34240499-C08FF1F3-B81A-4D56-9EFF-11894B3E3E59 Q34308495-AA43CBDA-766E-4B25-9C16-E8CF94493CBF Q34315871-BD4DA2EB-FEA4-413C-88A4-0283D2628829 Q34463820-E5F5588E-6786-4B9D-A804-C3F6A97A5E01 Q34661797-B0E21D37-DF4A-455D-B82A-3AEBE3869C2C Q34944820-1DDBFA1A-4B63-4D1B-9E57-F9F87F4F5518 Q35060537-EE2E8D7B-3F5C-4F0E-98D5-45DFCE648FBE Q35071704-E7436DAD-4342-457F-89A7-2D2FA0DDB7DF Q35236394-FA2347ED-7FA5-40CC-9DD7-A7DCDD80F5D9 Q35673900-8DF52FCD-2045-4EE8-BA41-26002D4CDAB1 Q35828288-364B7100-FC6F-4F3B-93A3-27869B1591CF Q35843507-E66A84C9-3AD6-4EF5-B2BE-1EDE14830868 Q36251577-BCB8D90E-EDF6-4075-BF30-1E015562935B Q36302853-474B82C4-B95F-4365-AC0B-9374DACA1FC3 Q36303665-AE97DBB6-4B1D-48E2-965B-011C2D724800 Q36317449-DE8B2191-B852-4240-9FE5-02B289DE9B3C Q36524400-F062BFF2-6DF6-42D7-A056-40D6EB081C36 Q36553375-85FBCF86-22A3-4F22-8B5B-6BCD3ABC00EC Q36813010-2BCD221E-055E-4C03-B6C1-2C6096CAEE28 Q36814620-D782FD50-167C-4B18-B812-DCB3CC3FAA3A Q36821053-DFC234CC-6916-4EBD-978B-199824CBC242 Q37017085-7CC56339-9F6A-4486-9BEB-FF62ED1C2BE4 Q37085326-2C0B8CDD-6173-4FDA-83A7-097CF5454391 Q37215023-64260A5E-51EA-4C38-9E85-856B3C59417D Q37571842-60042125-A11E-4884-BC67-7F9925B692D1

P2860

FOXO3 programs tumor-associated DCs to become tolerogenic in human and murine prostate cancer.

http://www.wikidata.org/entity/Q34755205

description

2011 nî lūn-bûn

@nan

2011 թուականի Մարտին հրատարակուած գիտական յօդուած

@hyw

2011 թվականի մարտին հրատարակված գիտական հոդված

@hy

2011年の論文

@ja

2011年論文

@yue

2011年論文

@zh-hant

2011年論文

@zh-hk

2011年論文

@zh-mo

2011年論文

@zh-tw

2011年论文

@wuu

name

FOXO3 programs tumor-associate ...... an and murine prostate cancer.

@ast

FOXO3 programs tumor-associate ...... an and murine prostate cancer.

@en

FOXO3 programs tumor-associate ...... an and murine prostate cancer.

@nl

type

label

FOXO3 programs tumor-associate ...... an and murine prostate cancer.

@ast

FOXO3 programs tumor-associate ...... an and murine prostate cancer.

@en

FOXO3 programs tumor-associate ...... an and murine prostate cancer.

@nl

prefLabel

FOXO3 programs tumor-associate ...... an and murine prostate cancer.

@ast

FOXO3 programs tumor-associate ...... an and murine prostate cancer.

@en

FOXO3 programs tumor-associate ...... an and murine prostate cancer.

@nl

P1433

Q34755205-64E11FF1-A90D-44B3-A062-231BD4D20C45

P1476

Q34755205-024A2B43-FD53-427B-91CF-E73FDCA15F01

P2093

Q34755205-29F648DF-1B00-4DCB-8957-3FFE99205C75

Q34755205-38E0CC54-9AA6-47F8-A26B-DC307E73C5C7

Q34755205-436E4486-6244-48AC-9B51-012112A61B20

Q34755205-6B070FCB-ED65-4FC5-8A21-06A67D98584E

Q34755205-6C57D8E5-C139-4EA2-8F44-258346B25C47

Q34755205-91ADC5AE-4377-40E3-8C26-0D4B3BB604DD

Q34755205-A42D06F2-3920-4DB4-A54D-81F2BA7B4022

Q34755205-DF0A1016-8826-4A7D-8011-37F399894D8C

P2860

Q34755205-00FAEA9D-5A05-4885-B350-237DD0B998B0

Q34755205-02D17BE3-A124-4302-9D7C-B39C0B3C4CC4

Q34755205-057D1E8C-AC4A-40B9-BF95-76E60EEBD956

Q34755205-1810E315-2DE3-46D6-9CE7-CE17CB6A9452

Q34755205-19C7680C-EAFC-4CCF-B86D-9F5E4D09DCFF

Q34755205-1D58A62B-ED6C-41FF-B32E-8077C07A858A

Q34755205-2F59EA44-E116-43C0-9BC6-D41E4390E53D

Q34755205-46D16E4C-AAFD-4137-A76E-2596FFDC4E2C

Q34755205-49CB4C09-47DC-41B5-9A53-0E33DB2AD630

Q34755205-4AA2F300-B136-40BB-91EC-FBFAFC09F969

P304

Q34755205-30A67E94-16C6-4612-8828-31908FF0139E

P31

Q34755205-4596C708-79DE-45CC-B742-5D80DF458F3D

P356

Q34755205-A217481C-EC21-4B99-9D36-CD1B731228EF

P407

Q34755205-69819CB2-84B2-4121-9F67-9DE75986C6A0

P433

Q34755205-1B3E4C4A-4079-4009-AF59-379A48D7BFAA

P478

Q34755205-D2E83D6F-6597-4DD8-B2BB-A311997BC335

P50

Q34755205-3F8AB888-D571-42A1-9CCA-7949E8005584

P577

Q34755205-47C7CC5D-DE2B-43E3-9AE4-2171EF48F4ED

P698

Q34755205-53C52EB2-44F8-486B-9681-08F93148B54B

P932

Q34755205-B0FBD886-D8DB-4B12-B6D9-0595DA18C2E9

P356

P1433

Journal of Clinical Investigation

P1476

FOXO3 programs tumor-associate ...... an and murine prostate cancer.

@en

P2093

Arthur A Hurwitz

http://www.w3.org/2001/XMLSchema#string

Elena Riboldi

http://www.w3.org/2001/XMLSchema#string

Katherine E R Stagliano

http://www.w3.org/2001/XMLSchema#string

Kim A Shafer-Weaver

http://www.w3.org/2001/XMLSchema#string

Martha M Sklavos

http://www.w3.org/2001/XMLSchema#string

Stefan Ambs

http://www.w3.org/2001/XMLSchema#string

Stephanie K Watkins

http://www.w3.org/2001/XMLSchema#string

Ziqiang Zhu

http://www.w3.org/2001/XMLSchema#string

P2860

Adoptive T cell therapy for cancer in the clinic

Functional interaction between beta-catenin and FOXO in oxidative stress signaling

Inhibition of indoleamine 2,3-dioxygenase in dendritic cells by stereoisomers of 1-methyl-tryptophan correlates with antitumor responses

Interleukin-15 rescues tolerant CD8+ T cells for use in adoptive immunotherapy of established tumors

Transforming growth factor-beta regulation of immune responses

Relative expression software tool (REST©) for group-wise comparison and statistical analysis of relative expression results in real-time PCR

STATs in cancer inflammation and immunity: a leading role for STAT3

IDO expression by dendritic cells: tolerance and tryptophan catabolism

Immunosuppressive strategies that are mediated by tumor cells

Plasmacytoid dendritic cells induce CD8+ regulatory T cells in human ovarian carcinoma.

P304

1361-1372

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1172/JCI44325

http://www.w3.org/2001/XMLSchema#string

P407

P433

4

http://www.w3.org/2001/XMLSchema#string

P478

121

http://www.w3.org/2001/XMLSchema#string

P50

P577

2011-03-23T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

21436588

http://www.w3.org/2001/XMLSchema#string

P932

3069771

http://www.w3.org/2001/XMLSchema#string